Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 1
2017 4
2019 1
2020 3
2021 3
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas.
Segura-Collar B, Garranzo-Asensio M, Herranz B, Hernández-SanMiguel E, Cejalvo T, Casas BS, Matheu A, Pérez-Núñez Á, Sepúlveda-Sánchez JM, Hernández-Laín A, Palma V, Gargini R, Sánchez-Gómez P. Segura-Collar B, et al. Cancer Res. 2021 Apr 15;81(8):2142-2156. doi: 10.1158/0008-5472.CAN-20-3558. Epub 2021 Feb 16. Cancer Res. 2021. PMID: 33593822 Free article.
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. Lassman AB, et al. Clin Cancer Res. 2022 Jun 1;28(11):2270-2277. doi: 10.1158/1078-0432.CCR-21-2664. Clin Cancer Res. 2022. PMID: 35344029 Free PMC article. Clinical Trial.
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, Weller M, Chinot O, De Vos FYFL, Whenham N, Sanghera P, Looman J, Kundu MG, Peter de Geus J, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfinopoulos V, Reijneveld JC, van den Bent MJ. Clement PMJ, et al. Among authors: sepulveda sanchez jm. Eur J Cancer. 2021 Apr;147:1-12. doi: 10.1016/j.ejca.2021.01.010. Epub 2021 Feb 15. Eur J Cancer. 2021. PMID: 33601293 Free article. Clinical Trial.
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Tannir NM, et al. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511. JAMA Oncol. 2022. PMID: 36048457 Free PMC article.
On optimal temozolomide scheduling for slowly growing glioblastomas.
Segura-Collar B, Jiménez-Sánchez J, Gargini R, Dragoj M, Sepúlveda-Sánchez JM, Pešić M, Ramírez MA, Ayala-Hernández LE, Sánchez-Gómez P, Pérez-García VM. Segura-Collar B, et al. Among authors: sepulveda sanchez jm. Neurooncol Adv. 2022 Sep 27;4(1):vdac155. doi: 10.1093/noajnl/vdac155. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36325374 Free PMC article.
Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study.
Vaz Salgado MA, Earl J, Berrocal VR, Arrieta FS, Gomez A, Sepulveda-Sanchez JM, Perez-Nuñez Á, de la Fuente EC, Lourido D, Villamayor M, Pian H, Muriel A, Rossi E, Zamarchi R, Carrato A, Ley L. Vaz Salgado MA, et al. Future Sci OA. 2022 May 24;8(5):FSO796. doi: 10.2144/fsoa-2022-0008. eCollection 2022 Mar. Future Sci OA. 2022. PMID: 35662744 Free PMC article.
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Gargini R, Segura-Collar B, Herránz B, García-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. Gargini R, et al. Among authors: sepulveda sanchez jm. Sci Transl Med. 2020 Jan 22;12(527):eaax1501. doi: 10.1126/scitranslmed.aax1501. Sci Transl Med. 2020. PMID: 31969485 Free PMC article.
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.
Segura-Collar B, Hiller-Vallina S, de Dios O, Caamaño-Moreno M, Mondejar-Ruescas L, Sepulveda-Sanchez JM, Gargini R. Segura-Collar B, et al. Among authors: sepulveda sanchez jm. Acta Neuropathol Commun. 2023 Jul 12;11(1):116. doi: 10.1186/s40478-023-01600-2. Acta Neuropathol Commun. 2023. PMID: 37438824 Free PMC article. No abstract available.
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas.
Gargini R, Segura-Collar B, Garranzo-Asensio M, Hortigüela R, Iglesias-Hernández P, Lobato-Alonso D, Moreno-Raja M, Esteban-Martin S, Sepúlveda-Sánchez JM, Nevola L, Sánchez-Gómez P. Gargini R, et al. Among authors: sepulveda sanchez jm. Neurotherapeutics. 2022 Jan;19(1):408-420. doi: 10.1007/s13311-021-01176-6. Epub 2022 Jan 31. Neurotherapeutics. 2022. PMID: 35099769 Free PMC article.
23 results